2431 related articles for article (PubMed ID: 22118442)
21. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
[TBL] [Abstract][Full Text] [Related]
22. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
24. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M;
Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
26. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
27. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Reyes F; Lepage E; Ganem G; Molina TJ; Brice P; Coiffier B; Morel P; Ferme C; Bosly A; Lederlin P; Laurent G; Tilly H;
N Engl J Med; 2005 Mar; 352(12):1197-205. PubMed ID: 15788496
[TBL] [Abstract][Full Text] [Related]
28. [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
Schneider T; Molnár Z; Deák B; Várady E; Tóth E; Csomor J; Matolcsy A; Lovey J; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2009 Nov; 150(44):2019-26. PubMed ID: 19861288
[TBL] [Abstract][Full Text] [Related]
29. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
31. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Tilly H; Lepage E; Coiffier B; Blanc M; Herbrecht R; Bosly A; Attal M; Fillet G; Guettier C; Molina TJ; Gisselbrecht C; Reyes F;
Blood; 2003 Dec; 102(13):4284-9. PubMed ID: 12920037
[TBL] [Abstract][Full Text] [Related]
32. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
33. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
[TBL] [Abstract][Full Text] [Related]
34. R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T; Yoshikawa T; Goto H; Sawada M; Yamada T; Fukuno K; Kasahara S; Shibata Y; Matsumoto T; Mabuchi R; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Nannya Y; Katsumura N; Takahashi T; Kito Y; Takami T; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2018 Oct; 36(4):638-644. PubMed ID: 29882279
[TBL] [Abstract][Full Text] [Related]
35. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
37. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
[TBL] [Abstract][Full Text] [Related]
38. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
39. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
